Biopharma Business

Tag "Targovax"

First patient recruited in Phase Ib trial of TG02

The first patient has been recruited in an exploratory Phase Ib clinical trial of Targovax’s second product from its RAS-peptide immunotherapy platform, TG02. In the open-label, non-randomised trial — to

Read Full Article

Norway Brings Another Cancer Vaccine to the Clinic

Targovax has recruited its first patient in a Phase Ib trial for its new cancer vaccine TG02 targeting mutations of the RAS gene. Mutations of the RAS gene disrupt normal cell

Read Full Article

Upcoming Events


The Magazine

New Subscriber

Subscribe Here